Source: Annual Congress 2004 - New aspects of drug therapy in paediatric asthma
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Bisgaard, M. L. Garcia Garcia, L. Gilles, J. Menten, C. Tozzi, P. Polos (Copenhagen, Denmark; Madrid, Spain; Whitehouse Station, United States Of America). Montelukast reduces viral-induced asthma exacerbations: the PREVIA study. Eur Respir J 2004; 24: Suppl. 48, 1348

Member's Comments

No comment yet.

Related content which might interest you: Could montelukast reduce asthma exacerbations? Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Montelukast and frequency of exacerbations of asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005 Increase in α-defensins during rhinovirus-induced experimental asthma exacerbations Source: Eur Respir J 2006; 28: Suppl. 50, 154s Year: 2006 Tiotropium reduces COPD exacerbations: the MISTRAL study Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004 Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 Characterising asthma exacerbations in the CAPTAIN trial Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Montelukast in cases of severe asthma Source: Eur Respir J 2002; 20: Suppl. 38, 407s Year: 2002 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Bacterial lysates in the prevention of asthma exacerbations in uncontrolled asthma: the Breathe study Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Montelukast and the prevention of viral induced asthma (The PREVIA Study) Source: Eur Respir J 2003; 22: Suppl. 45, 533s Year: 2003 Late Breaking Abstract: Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Dexamethasone or prednisolone for acute asthma exacerbations in children: a meta-analysis Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Montelukast as add-on therapy in severe noninfectious COPD exacerbations Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009